Cyteir Therapeutics, Inc.
NASDAQ:CYT
3.02 (USD) • At close March 15, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Cyteir Therapeutics, Inc. |
Symbool | CYT |
Munteenheid | USD |
Prijs | 3.02 |
Beurswaarde | 108,714,262 |
Dividendpercentage | 0% |
52-weken bereik | 1.65 - 3.19 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Markus F. Renschler M.D. |
Website | https://cyteir.com |
An error occurred while fetching data.
Over Cyteir Therapeutics, Inc.
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)